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was randomly selected from the back-
ground population, and there was virtually
no loss to follow-up because of the precise
linkage between the study cohort and
various Danish health registries.
In conclusion, the results of this large
population-based cohort study showed
no convincing association between obe-
sity and risk for MM, whereas inverse
associations were found between var-
ious anthropometric measures and risk
for BCC in both genders and for SCC
among women only. Additional studies
with more accurate data on exposure to
UVR are needed to investigate the role
of obesity in skin cancer pathogenesis.
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TO THE EDITOR
We report a total population study on
the incidence and mortality of neurofi-
bromatosis 1 (NF1) and 2 (NF2). The
results show that the birth incidence
of NF1 is higher than that generally
reported. These results also show that
this life-threatening disease is more
deleterious to women than to men.
NF1 is an autosomal dominant
neurocutaneous disease caused by
mutations in the NF1 gene on chromo-
some 17 (for review see Jouhilahti et al.,
2011). NF2 is also a dominantly
inherited disease, but caused by
mutations in the NF2 gene on chromo-
some 22 (Rouleau et al., 1993). An
important milestone for NF studies was
the consensus conference of National
Institutes of Health (NIH) in 1987,
which outlined the clinical diagnostic
criteria for NF1 and NF2 (Stumpf et al.,
1988). Four main diagnostic signs of
NF1 are visible in skin: cafe´-au-lait
spots, dermal neurofibromas, axillary
freckles, and some plexiform neuro-
fibromas. The hallmarks of NF2 include
bilateral vestibular schwannomas, other
schwannomas, and intracranial menin-
geomas (Evans et al., 1992).
Most of the NF1 epidemiological
studies report prevalences between
1/3,000 and 1/6,000 and birth incidence
with estimates varying between 1/2,558Accepted article preview online 29 October 2014; published online 4 December 2014
Abbreviations: ICD, International Classification of Diseases; NF, neurofibromatosis; SMR, standardized
mortality ratio
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and 1/3,333 (Huson et al., 1989;
Poyhonen et al., 2000; Lammert et al.,
2005; Evans et al., 2010; Supplementary
Table S1 online). NF2 is markedly less
common than NF1. The reported inci-
dences of NF2 have varied between
1/33,000 (Evans et al., 2010) and
1/87,410 (Antinheimo et al., 2000).
Mortality in NF1 has previously been
studied, e.g., in cohorts from France,
Wales, US, and Denmark (Srensen
et al., 1986; Rasmussen et al., 2001;
Duong et al., 2011; Evans et al., 2011).
These studies have shown excess
mortality of NF1 patients compared
with the general population and a
high proportion of deaths caused by
malignancies.
The present study was carried out in
Finland, with a population of 5.4 mil-
lion. The national health registers are
comprehensive and accurate (Teppo
et al., 1994; Gissler and Haukka,
2004). The ascertainment was based
on hospital records of all patients identi-
fied from the hospital registers since
1987. ICD (International Classification
of Diseases) coding was used to search
patients in electronic hospital registers,
which cover all medical specialties in
all secondary and tertiary centers in
Finland. To verify NF1 and NF2 dia-
gnoses, the patient records and autopsy
reports were carefully reviewed. We
confirmed diagnosis of a total of 1,471
patients with NF1 and 90 patients with
NF2 (Supplementary Figure S1 online).
This patient material was analyzed for
incidence, mortality, and causes of
death. In addition, 209 patients
were suspected to have NF1. The major-
ity of these were children who did not
fulfill the NIH criteria by the end of the
study.
In the current study, the peak inci-
dence of a 3-year period for NF1 was
1/1,871, noted in 1994–1996 (Supple-
mentary Figure S2a online). This appar-
ently represents a good estimate of the
true incidence of NF1 and shows that
the estimated birth incidence of NF1 is
closer to 1/2,000 than to the generally
accepted 1/3,000. This high figure may
result from efficient ascertainment using
Table 1. The SMR for deaths of individuals with NF1 for selected medical conditions of 214 deaths in 1987–2012
Condition ICD codes Gender Observed Expected SMR (95% CI)
Malignant neoplasms ICD-9: 140–208, 238.6, 273.3
ICD-10: C00–C97
Male 45 8.26 5.45 (4.02–7.23)
Female 57 8.37 6.81 (5.21–8.76)
Maleþ female 102 16.62 6.14 (5.03–7.42)
Cardiovascular ICD-9: 289.1–289.2, 390–425.4, 425.8–434,
436–437.6, 437.8X–444, 447–459
ICD-10: I00–I99
Male 26 14.27 1.82 (1.22–2.63)
Female 17 9.51 1.79 (1.08–2.80)
Maleþ female 43 23.78 1.81 (1.33–2.41)
Respiratory ICD-9: 034.0, 460–519, 799.1
ICD-10: J00–J99
Male 7 2.20 3.19 (1.39–6.30)
Female 6 1.23 4.88 (2.00–10.14)
Maleþ female 13 3.43 3.79 (2.11–6.32)
Dementia ICD-9: 290, 331.0, 437.8A (290.4), 797
ICD-10: F01, F03, G30
Male 4 1.02 3.92 (1.25–9.45)
Female 3 1.14 2.63 (0.67–7.17)
Maleþ female 7 2.19 3.20 (1.40–6.32)
External causes excluding alcohol ICD-9: E800–E840, E850, E860–E990
ICD-10: V01–Y89, Y92–Y98
Male 6 6.82 0.88 (0.36–1.83)
Female 2 2.56 0.78 (0.13–2.56)
Maleþ female 8 9.38 0.85 (0.40–1.62)
o50 years All Male 39 9.14 4.27 (3.08–5.78)
Female 47 4.50 10.44 (7.76–13.76)
Maleþ female 86 13.64 6.31 (5.08–7.75)
450 years All Male 65 29.89 2.17 (1.69–2.75)
Female 63 22.84 2.76 (2.14–3.51)
Maleþ female 128 52.73 2.43 (2.03–2.88)
Total All Male 104 39.03 2.66 (2.19–3.22)
Female 110 27.34 4.02 (3.32–4.83)
Maleþ female 214 66.37 3.22 (2.81–3.68)
Abbreviations: CI, confidence interval; ICD, International Classification of Diseases; SMR, standardized mortality ratio.
The expected number of deaths was calculated by multiplying the sex-, age-, and calendar period–specific numbers of person-years by the respective mortality
rates in the Finnish population achieved from Statistics Finland (Official Statistics of Finland: Causes of death, http://tilastokeskus.fi/til/ksyyt/index_en.html,
accessed 16 June 2014 and Official Statistics of Finland: Population structure, http://tilastokeskus.fi/til/vaerak/index.html, accessed 16 June 2014).
E Uusitalo et al.
Incidence and Mortality of Neurofibromatosis
www.jidonline.org 905
electronic registers operative in all of
Finland (Teppo et al., 1994). We also
believe that the increasing numbers in
the 1990s are related to enhanced
efficacy in making the diagnosis,
which is likely owing to the general
awareness of NF1 and the timing of
our data collection, which included
hospital visits since 1987. Established
in 1987, the NIH diagnostic criteria
have facilitated diagnosing NF in patients
born since the 1980s (Stumpf et al.,
1988). The patients born in the mid-
1990s were old enough to fulfill the NIH
criteria by the time of our patient search,
and the children born in 1990s have
been diagnosed and followed up by
specialists and are thus better covered
in this study. The incidence of B1/
1,900 represents minimum incidence,
as only verified diagnoses were included,
and the cohort ascertainment may
still exclude patients with very mild or
undiagnosed NF1.
For NF2, the highest incidence in a
10-year period was noted in persons
born between 1970 and 1979 and was
B1/39,000. This is in line with previous
estimates, which have varied between
1/33,000 (Evans et al., 2010) and 1/
87,410 (Antinheimo et al., 2000). A
total of 23 NF2 patients had died
(Supplementary Table S3 online). The
age at death varied from 19 to 80 years,
the average age at death being 43.6 and
median 40.9 years. It is worth noting
that NF was registered as an underlying
cause of death in 14/23 (61%) death
certificates.
Excess mortality has been reported in
NF1, which is mainly explained by
malignancies. In our study, the Causes
of Death Register run yielded 248 NF1
deaths, of which 214 occurred in 1987–
2012 (Supplementary Table S2 and
Figure S2b online). The mean age
at death was 52.3 years in men and
51.9 years in women, whereas the
corresponding numbers, obtained from
Statistics Finland, were 68.8 and 78.0
years in the general population, respec-
tively. Thus, the life span was shortened
by 16.5 years in men and by 26.1 years
in women with NF1. We point out that
the overall toll of NF1 on gender mor-
tality rates is affected by women’s over-
all higher life expectancy. Previous
studies have reported an 8- to 15-year
decrease in life expectancy in NF1
patients (Zo¨ller et al., 1995; Evans
et al., 2011). However, the median age
of our patients was 33.3 years at the end
of the follow-up, which may cause bias
toward younger age.
The finding that NF1 shortens the life
span in women to a greater extent than
in men is also explained by the fact that
standardized mortality ratios (SMRs) for
all but cardiovascular deaths and
dementia were higher in women than
in men (Table 1). Specifically, the SMR
was 10.4 in women but only 4.3 in men
under 50 years of age. The increased
SMR in both sexes is largely explained
by malignant neoplasms at a relatively
young age. It is also worth noting that
after the age of 50 years the effect of
gender on the SMR in NF1 became
considerably less significant.
To conclude, our findings highlight
the facts that the birth incidence of
1:2000 in NF1 is higher than that gen-
erally reported, and that NF1 reduces
the life expectancy of women consider-
ably more than that of men.
CONFLICT OF INTEREST
The authors state no conflict of interest.
ACKNOWLEDGMENTS
Eetu Heerva¨ is acknowledged for participating in
the data collection. This study was funded by
grants from Academy of Finland, Turku University
Hospital, The Finnish Cancer Organisations, and
the Turku University Foundation.
Elina Uusitalo1,7, Jussi Leppa¨virta2,7,
Anna Koffert2, Sakari Suominen3,4,
Jussi Vahtera3, Tero Vahlberg5,
Minna Po¨yho¨nen6, Juha Peltonen1 and
Sirkku Peltonen2
1Department of Cell Biology and Anatomy,
University of Turku, Turku, Finland;
2Department of Dermatology, University of
Turku and Turku University Hospital, Turku,
Finland; 3Department of Public Health,
University of Turku and Turku University
Hospital, Turku, Finland; 4Nordic School of
Public Health, Gothenburg, Sweden;
5Department of Biostatistics, University of Turku,
Turku, Finland and 6Department of Clinical
Genetics, HUSLAB Helsinki University Central
Hospital and Department of Medical Genetics,
University of Helsinki, Helsinki, Finland
E-mail: juhpel@utu.fi
7These authors contributed equally to this work.
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online
version of the paper at http://www.nature.com/jid
REFERENCES
Antinheimo J, Sankila R, Carpe´n O et al. (2000)
Population-based analysis of sporadic
and type 2 neurofibromatosis-associated
meningiomas and schwannomas. Neurology
54:71–6
Duong TA, Sbidian E, Valeyrie-Allanore L et al.
(2011) Mortality associated with neurofibro-
matosis 1: a cohort study of 1895 patients in
1980-2006 in France. Orphanet J Rare Dis
6:18
Evans DG, Howard E, Giblin C et al. (2010) Birth
incidence and prevalence of tumor-prone
syndromes: estimates from a UK family
genetic register service. Am J Med Genet A
152A:327–32
Evans DG, Huson SM, Donnai D et al. (1992)
A clinical study of type 2 neurofibromatosis.
Q J Med 84:603–18
Evans DG, O’Hara C, Wilding A et al. (2011)
Mortality in neurofibromatosis 1: in North
West England: an assessment of actuarial
survival in a region of the UK since 1989.
Eur J Hum Genet 19:1187–91
Gissler M, Haukka J (2004) Finnish health and
social welfare registers in epidemiological
research. Norsk Epidemiologi 14:113–20
Huson S, Compston D, Clark P et al. (1989) A gene-
tic study of von Recklinghausen neurofibroma-
tosis in south east Wales. I. Prevalence, fitness,
mutation rate, and effect of parental transmis-
sion on severity. J Med Genet 26:704–11
Jouhilahti EM, Peltonen S, Heape AM et al. (2011)
The pathoetiology of neurofibromatosis 1. Am
J Pathol 178:1932–9
Lammert M, Friedman J, Kluwe L et al. (2005)
Prevalence of neurofibromatosis 1 in German
children at elementary school enrollment.
Arch Dermatol 141:71–4
Poyhonen M, Kyto¨la¨ S, Leisti J (2000) Epidemiology
of neurofibromatosis type 1 (NF1) in northern
Finland. J Med Genet 37:632–6
Rasmussen SA, Yang Q, Friedman JM (2001)
Mortality in neurofibromatosis 1: an analysis
using U.S. death certificates. Am J Hum Genet
68:1110–8
Rouleau GA, Merel P, Lutchman M et al. (1993)
Alteration in a new gene encoding a putative
membrane-organizing protein causes neuro-
fibromatosis type 2. Nature 363:515–21
Stumpf D, Alksne J, Annegers J et al. (1988) Neuro-
fibromatosis. Conference statement. National
Institutes of Health Consensus Development
Conference. Archives of Neurology 45:575–8
Srensen SA, Mulvihill JJ, Nielsen A (1986)
Long-term follow-up of von Recklinghausen
neurofibromatosis. Survival and malignant
neoplasms. N Engl J Med 314:1010–5
Teppo L, Pukkala E, Lehtonen M (1994) Data
quality and quality control of a population-
based cancer registry. Experience in Finland.
Acta Oncol 33:365–9
Zo¨ller M, Rembeck B, Akesson HO et al. (1995)
Life expectancy, mortality and prognostic
factors in neurofibromatosis type 1. A
twelve-year follow-up of an epidemiological
study in Go¨teborg, Sweden. Acta Derm
Venereol 75:136–40
E Uusitalo et al.
Incidence and Mortality of Neurofibromatosis
906 Journal of Investigative Dermatology (2015), Volume 135
